Trial Profile
A Phase II Study of Lenvatinib, a Multi-Targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2018
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 31 Jan 2018 New trial record